Sort
130,381 grants matching “hiv”
Retrovirus Assembly and Maturation
$958,126Alan Rein · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
PEDIATRIC AIDS CLINICAL TRIALS GROUP
$958,057Columbia University Health Sciences · U01 · FY2001 · AI
Linking Antibody Cooperativity and Effector Cell Engagement
$958,020Guido Ferrari · Duke University · P01 · FY2023 · AI
Identification of the Initial Targets of Transmission
$958,017Thomas Hope · Northwestern University At Chicago · R01 · FY2015 · AI
NIH Director's Pioneer Award (RMI)
$958,000J. David Gladstone Institutes · DP1 · FY2004 · OD
Cocaine HIV/AIDS, and Antiretrovirals
$957,992William Lewis · Emory University · R01 · FY2011 · DA
Embedding Pharmacogenotyping in an Integrated Health System for the Underserved
$957,981Todd C. Skaar · Indiana University Indianapolis · U01 · FY2015 · HG
Design and testing of germline-targeting and boosting immunogens to elicit 10E8-like broadly neutralizing antibodies against HIV
$957,981William R Schief · Scripps Research Institute, The · R01 · FY2019 · AI
Innate Immunity and HIV Restriction
$957,933John C Reed · Salk Institute For Biological Studies · P01 · FY2011 · AI
Portable electronically controlled transdermal patch for enfuvirtide delivery
$957,909Maureen L. Mulvihill · Actuated Medical, Inc. · R44 · FY2012 · AI
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.
$957,844Iain James Macleod · Aldatu Biosciences, Inc. · SB1 · FY2024 · AI
HIV/AIDS International Training Program
$957,748Christopher C. Whalen · Case Western Reserve University · D43 · FY2006 · TW
CBMHR Administrative Core
$957,604Dong Liang · Texas Southern University · U54 · FY2023 · MD
Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies
$957,548Laurent Karl Verkoczy · Applied Biomedical Science Institute · R01 · FY2021 · AI
Core 3: Biocontainment Research Support Services Core
$957,509Colin S. Duckett · Duke University · UC7 · FY2024 · AI
Linking Antibody Cooperativity and Effector Cell Engagement
$957,431Guido Ferrari · Duke University · P01 · FY2022 · AI
Targeted therapies for Kaposi sarcoma and KSHV-multicentric Castleman disease
$957,389Ramya Ramaswami · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Experimental and Analytical Resource Core
$957,353Liz Simon · Lsu Health Sciences Center · P60 · FY2021 · AA
Phase 1/2 trial of Pharmacological HIV-1 Prevention
$957,316University Of California San Francisco · U01 · FY2004 · AI
Correlates of protective immunity to HCV and rational vaccine design: Project 3
$957,184Rama Rao Amara · Emory University · U19 · FY2023 · AI
REPRIEVE - DCC
$957,177Udo Hoffmann · Massachusetts General Hospital · U01 · FY2016 · HL
Data and analysis ecosystem for eukaryotic pathogen targeted sequencing
$957,169Bryan R Greenhouse · University Of California, San Francisco · U01 · FY2025 · AI
Influence of viral and immune interventions on early events following oral SIV infection
$957,147Donald L Sodora · Seattle Children'S Hospital · R01 · FY2023 · DE
EXPANDED HIV TESTING PREVELANCE HEALTH CARE SETTINGS TO ADDRESS RACIAL/ETHIC DISP
$957,131Liisa Randall · Michigan State Department Of Health And Human Services · U62 · FY2007 · PS
Safety and Tolerability of Ultra-short Course Rifapentine and Isoniazid (1HP) for Prevention of Tuberculosis in HIV-Uninfected Individuals
$957,056Richard E Chaisson · Johns Hopkins University · U01 · FY2022 · AI